Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 108

Interferon alpha was the first cytokine to be produced using rDNA technology.¹⁸ Interferon is a regulator of growth and differentiation and has clinical efficacy in malignant, viral, immunologic, angiogenic, inflammatory, and fibrotic diseases. Interferon‐beta was approved by the FDA in 1993 and is the oldest and most frequently used medication for treating multiple sclerosis to date.¹⁸ Interferon (IFN) works in multiple sclerosis in a variety of ways, decreasing proinflammatory cytokines while also leading to the production of anti‐inflammatory cytokines by increasing the activity of suppressor T‐cells. The activity of cytokines also makes for a strong candidate in oncology. IFN‐alpha was found to have tumor suppressing activity in a rare B‐cell neoplasm, which led to expansive research throughout the 1990s on clinical utilization of the molecule for cancer treatment.¹⁹ Intron A^® as found in Table 3.5 is approved for five unique cancer types.